Orion Diagnostica Readying Respiratory Test for Point-of-Care MDx System

Oct 31, 2017

|

Premium

NEW YORK (GenomeWeb) – Orion Diagnostica, a wholly-owned subsidiary of Finland's largest healthcare company, Orion Group, continues to develop assays for its point-of-care isothermal amplification-based molecular diagnostic platform, GenRead, and aims to eventually bring its molecular technologies to the US.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

May

22

Featured Webinar

A Digital PCR Liquid Biopsy Workflow for Mutation Detection and Therapeutic Monitoring

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Jun

18

Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.

Jun

19

Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Menu